| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
66,383,000 |
| Market
Cap: |
1.33(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$16.53 - $28.72 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 2 |
| Insider 6 Months : 2 |
| Insider 3/6 Months : 4.3 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Xencor is a clinical-stage biopharmaceutical company focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. Co. is developing a portfolio of clinical-stage XmAb® drug candidates from its protein engineering technology platforms. Co.'s XmAb bispecific Fc drug candidates include: Vudalimab (XmAb717), which is a bispecific antibody that targets PD-1 and CTLA-4 and for patients with metastatic castration-resistant prostate cancer and other solid tumor types; and Plamotamab, which is a bispecific antibody that targets CD20, an antigen on B-cell tumors, and CD3, an activating receptor on T cells.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
53 |
53 |
53 |
53 |
| Total Buy Value |
$1,013 |
$1,013 |
$1,013 |
$1,013 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
1 |
1 |
1 |
| Total Shares Sold |
101,351 |
146,351 |
179,848 |
214,693 |
| Total Sell Value |
$2,152,463 |
$3,094,133 |
$3,971,419 |
$5,040,525 |
| Total People Sold |
5 |
5 |
5 |
6 |
| Total Sell Transactions |
10 |
11 |
12 |
27 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Dahiyat Bassil I |
PRESIDENT & CEO |
• • – |
2022-03-09 |
4 |
S |
$29.00 |
$72,326 |
D/D |
(2,494) |
207,815 |
|
-6% |
|
| Kuch John J |
SR. VICE PRESIDENT & CFO |
• – – |
2022-03-09 |
4 |
S |
$28.93 |
$19,965 |
D/D |
(690) |
124,591 |
|
-6% |
|
| Desjarlais John R |
SR. VICE PRESIDENT & CSO |
• – – |
2022-03-09 |
4 |
S |
$29.13 |
$34,140 |
D/D |
(1,172) |
135,625 |
|
-6% |
|
| Yang Allen |
SR. VICE PRESIDENT & CMO |
• – – |
2022-03-09 |
4 |
S |
$28.94 |
$34,723 |
D/D |
(1,200) |
66,529 |
|
-6% |
|
| Yang Allen |
SR. VICE PRESIDENT & CMO |
• – – |
2022-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
33,174 |
67,729 |
|
- |
|
| Dahiyat Bassil I |
PRESIDENT & CEO |
• • – |
2022-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
49,761 |
210,309 |
|
- |
|
| Dahiyat Bassil I |
PRESIDENT & CEO |
• • – |
2022-03-03 |
4 |
S |
$29.90 |
$87,581 |
D/D |
(2,929) |
160,548 |
|
-4% |
|
| Eckert Celia |
VP, GENERAL COUNSEL |
• – – |
2022-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
19,904 |
29,765 |
|
- |
|
| Eckert Celia |
VP, GENERAL COUNSEL |
• – – |
2022-03-03 |
4 |
S |
$29.91 |
$13,487 |
D/D |
(451) |
9,861 |
|
-4% |
|
| Kuch John J |
SR. VICE PRESIDENT & CFO |
• – – |
2022-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
23,222 |
125,281 |
|
- |
|
| Kuch John J |
SR. VICE PRESIDENT & CFO |
• – – |
2022-03-03 |
4 |
S |
$29.86 |
$28,994 |
D/D |
(971) |
102,059 |
|
-4% |
|
| Desjarlais John R |
SR. VICE PRESIDENT & CSO |
• – – |
2022-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
35,828 |
136,797 |
|
- |
|
| Desjarlais John R |
SR. VICE PRESIDENT & CSO |
• – – |
2022-03-03 |
4 |
S |
$29.86 |
$37,032 |
D/D |
(1,240) |
100,969 |
|
-4% |
|
| Yang Allen |
SR. VICE PRESIDENT & CMO |
• – – |
2021-12-17 |
4 |
S |
$36.62 |
$134,178 |
D/D |
(3,664) |
34,555 |
|
34% |
|
| Kuch John J |
SR. VICE PRESIDENT & CFO |
• – – |
2021-06-29 |
4 |
OE |
$11.05 |
$230,497 |
D/D |
17,821 |
109,386 |
|
- |
|
| Kuch John J |
SR. VICE PRESIDENT & CFO |
• – – |
2021-03-08 |
4 |
A |
$0.00 |
$0 |
D/D |
6,021 |
91,436 |
|
- |
|
| Eckert Celia |
VP, GENERAL COUNSEL |
• – – |
2021-03-08 |
4 |
A |
$0.00 |
$0 |
D/D |
6,021 |
9,517 |
|
- |
|
| Desjarlais John R |
SR. VICE PRESIDENT & CSO |
• – – |
2021-03-08 |
4 |
A |
$0.00 |
$0 |
D/D |
10,421 |
102,209 |
|
- |
|
| Dahiyat Bassil I |
PRESIDENT & CEO |
• • – |
2021-03-08 |
4 |
A |
$0.00 |
$0 |
D/D |
21,999 |
163,063 |
|
- |
|
| Yang Allen |
SR. VICE PRESIDENT & CMO |
• – – |
2021-03-08 |
4 |
A |
$0.00 |
$0 |
D/D |
9,263 |
37,658 |
|
- |
|
| Kuch John J |
SR. VICE PRESIDENT & CFO |
• – – |
2021-03-03 |
4 |
AS |
$45.09 |
$36,293 |
D/D |
(805) |
85,415 |
|
-24% |
|
| Dahiyat Bassil I |
PRESIDENT & CEO |
• • – |
2021-03-03 |
4 |
S |
$44.88 |
$127,909 |
D/D |
(2,850) |
141,064 |
|
24% |
|
| Desjarlais John R |
SR. VICE PRESIDENT & CSO |
• – – |
2021-03-03 |
4 |
S |
$45.03 |
$52,454 |
D/D |
(1,165) |
91,788 |
|
24% |
|
| Eckert Celia |
VP, GENERAL COUNSEL |
• – – |
2021-03-03 |
4 |
S |
$44.94 |
$19,955 |
D/D |
(444) |
3,496 |
|
24% |
|
| Kuch John J |
SR. VICE PRESIDENT & CFO |
• – – |
2021-03-01 |
4 |
AS |
$48.90 |
$736,672 |
D/D |
(15,065) |
86,220 |
|
-29% |
|
312 Records found
|
|
Page 3 of 13 |
|
|
0.75 (3.9%) 
